{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:26:48Z","timestamp":1784647608917,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.oftale.2023.11.011","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T17:06:39Z","timestamp":1700931999000},"page":"158-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Iatrogenic affectation of ocular motility by immune checkpoint inhibitors"],"prefix":"10.1016","volume":"99","author":[{"given":"H.","family":"Fern\u00e1ndez Jim\u00e9nez-Ortiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Maroto Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Lapuente Monjas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sampedro Y\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"S\u00e1nchez Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Toledano Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oftale.2023.11.011_bib0005","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14737140.2017.1296765","article-title":"Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review","volume":"17","author":"Abdel-Rahman","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.oftale.2023.11.011_bib0010","doi-asserted-by":"crossref","first-page":"1130238","DOI":"10.3389\/fimmu.2023.1130238","article-title":"Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors","volume":"14","author":"Gan","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.oftale.2023.11.011_bib0015","first-page":"1","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.oftale.2023.11.011_bib0020","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.oftale.2023.11.011_bib0025","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina Phila Pa"},{"key":"10.1016\/j.oftale.2023.11.011_bib0030","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/pds.5108","article-title":"Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database","volume":"29","author":"Hasegawa","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.oftale.2023.11.011_bib0035","doi-asserted-by":"crossref","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.oftale.2023.11.011_bib0040","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ajo.2020.12.013","article-title":"Population-based frequency of ophthalmic adverse events in melanoma, other cancers, and after immune checkpoint inhibitor treatment","volume":"224","author":"Braun","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oftale.2023.11.011_bib0045","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/978-3-030-41008-7_17","article-title":"Immune-related oral, otologic, and ocular adverse events","volume":"1244","author":"Srivastava","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.oftale.2023.11.011_bib0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.oftale.2023.11.011_bib0055","doi-asserted-by":"crossref","first-page":"e866","DOI":"10.1212\/WNL.0000000000011340","article-title":"Cranial nerve disorders associated with immune checkpoint inhibitors","volume":"96","author":"Vogrig","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.oftale.2023.11.011_bib0060","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1136\/bjophthalmol-2020-316970","article-title":"Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience","volume":"105","author":"Fortes","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oftale.2023.11.011_bib0065","series-title":"Drug and therapeutics committees: a practical guide","author":"Holloway","year":"2020"},{"key":"10.1016\/j.oftale.2023.11.011_bib0070","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annder.2013.02.029","article-title":"[Orbital myositis associated with ipilimumab]","volume":"140","author":"Lecouflet","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.oftale.2023.11.011_bib0075","first-page":"381","article-title":"Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma","volume":"37","author":"Alnabulsi","year":"2018","journal-title":"Orbit Amst Neth"},{"key":"10.1016\/j.oftale.2023.11.011_bib0080","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/IOP.0b013e3181ef72a1","article-title":"Drug-induced graves disease from CTLA-4 receptor suppression","volume":"27","author":"Borodic","year":"2011","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.oftale.2023.11.011_bib0085","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/CJI.0000000000000161","article-title":"Myasthenia gravis after nivolumab therapy for squamous cell carcinoma of the bladder","volume":"40","author":"Chang","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.oftale.2023.11.011_bib0090","doi-asserted-by":"crossref","first-page":"e402","DOI":"10.1093\/oncolo\/oyac033","article-title":"Consider myocarditis when patients treated with immune checkpoint inhibitors present with ocular symptoms","volume":"27","author":"Rhee","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.oftale.2023.11.011_bib0095","doi-asserted-by":"crossref","first-page":"669493","DOI":"10.3389\/fneur.2021.669493","article-title":"Pembrolizumab-induced isolated cranial neuropathy: a rare case report and review of literature","volume":"12","author":"Bruno","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.oftale.2023.11.011_bib0100","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/01658107.2019.1566385","article-title":"Isolated abducens nerve palsy following pembrolizumab","volume":"44","author":"Jaben","year":"2020","journal-title":"Neuroophthalmology"},{"key":"10.1016\/j.oftale.2023.11.011_bib0105","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.nmd.2020.02.013","article-title":"Immune checkpoint inhibitors (ICIs)-related ocular myositis","volume":"30","author":"Garibaldi","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.oftale.2023.11.011_bib0110","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3390\/brainsci12091242","article-title":"Camrelizumab-induced isolate abducens neuritis: a rare ophthalmic immune-related adverse events","volume":"12","author":"Hou","year":"2022","journal-title":"Brain Sci"},{"key":"10.1016\/j.oftale.2023.11.011_bib0115","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/WNF.0000000000000464","article-title":"Severe demyelinating polyneuropathy and cranial neuropathy during avelumab treatment of metastatic merkel cell carcinoma","volume":"44","author":"Bili\u0107","year":"2021","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.oftale.2023.11.011_bib0120","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ana.25708","article-title":"Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.oftale.2023.11.011_bib0125","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1080\/09273948.2019.1583347","article-title":"Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies","volume":"28","author":"Noble","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.oftale.2023.11.011_bib0130","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ophtha.2020.11.001","article-title":"Ophthalmic immune-related adverse events after anti-CTLA-4 or PD-1 therapy recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry","volume":"128","author":"Sun","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oftale.2023.11.011_bib0135","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11096-022-01395-7","article-title":"Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system","volume":"44","author":"Chen","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.oftale.2023.11.011_bib0140","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nmd.2019.10.006","article-title":"Nivolumab and ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation","volume":"30","author":"Valenti-Azcarate","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.oftale.2023.11.011_bib0145","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.21037\/apm-20-454","article-title":"Immunotherapy-related skeletal muscle weakness in cancer patients: a case series","volume":"10","author":"Ng","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.oftale.2023.11.011_bib0150","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1111\/1759-7714.13177","article-title":"Myasthenia gravis and myopathy after nivolumab treatment for non-small cell lung carcinoma: a case report","volume":"10","author":"Kim","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.oftale.2023.11.011_bib0155","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1177\/1078155220976797","article-title":"Late-onset double-seronegative myasthenia gravis syndrome and myasthenic crisis due to nivolumab use for Hodgkin\u2019s lymphoma","volume":"27","author":"Dang","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.oftale.2023.11.011_bib0160","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418799864","article-title":"Neurological complications of immune checkpoint inhibitors: what happens when you \u00abtake the brakes off\u00bb the immune system","volume":"11","author":"Dalakas","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.oftale.2023.11.011_bib0165","doi-asserted-by":"crossref","first-page":"701951","DOI":"10.3389\/fimmu.2021.701951","article-title":"Ocular immune-related adverse events associated with immune checkpoint inhibitors in lung cancer","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"}],"container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173579423001883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173579423001883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T10:43:10Z","timestamp":1712227390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173579423001883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2173579423001883"],"URL":"https:\/\/doi.org\/10.1016\/j.oftale.2023.11.011","relation":{},"ISSN":["2173-5794"],"issn-type":[{"value":"2173-5794","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Iatrogenic affectation of ocular motility by immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oftale.2023.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Sociedad Espa\u00f1ola de Oftalmolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}